In vitro synergistic antifungal activity of silybin-posaconazole combination against Candida auris
- 1Department of Dermatology, Hubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infection, Jingzhou Hospital Affiliated to Yangtze University
- 2Department of Clinical Medicine, Yangtze University
- 3Department of Ophthalmology, Jingzhou Hospital Affiliated to Yangtze University
Abstract
Background: Candida auris infections pose a severe global public health threat. The hepatotoxicity of conventional azole antifungals and biofilm-mediated drug resistance adversely affect their clinical application. The natural component silybin (SLB) has both hepatoprotective and antimicrobial activities.
Methods: This study was conducted in accordance with the CLSI M27-A4 standard, employing the broth microdilution plate method to evaluate the efficacy of SLB combined with itraconazole (ITR), voriconazole (VOR), posaconazole (POS) and fluconazole (FLC) against 10 C. auris strains. Synergistic effects were determined by measuring minimum inhibitory concentrations (MICs) and fractional inhibition concentration indices (FICIs). Potential synergistic mechanisms were investigated using ergosterol quantification, biofilm inhibition assay, reactive oxygen species (ROS) detection, Real-Time Quantitative PCR, SYTO9/PI double staining assay, and XTT assay.
Results: Antifungal susceptibility testing showed that synergistic effects were most frequently observed when SLB was combined with POS (70% of strains), followed by SLB-VOR (50%) and SLB-ITR (30%). No synergism was detected for the SLB-FLC combination, while antagonism was observed in one strain for the SLB-ITR combination. The SLB-POS combination reduced ergosterol content, inhibited biofilm formation, and decreased the viability of preformed mature biofilms. It induced ROS accumulation, downregulated the expression of biofilm-associated genes ( bcr1 , efg1 , scf1 , mkc1 , erg2 , erg11 , als5 ) under planktonic conditions, and suppressed biofilm proliferative activity.
Conclusion: The SLB-POS combination exhibits synergistic antifungal activity against C. auris. Its activity is associated with multiple pathways, including elevated oxidative stress responses and reduced ergosterol content. In addition, this combination downregulates biofilm-related gene expression and impairs the capacity of planktonic cells to form biofilms. These findings provide preliminary experimental evidence for addressing C. auris drug resistance and support further investigation of this combination as a therapeutic strategy with an improved safety-efficacy profile and potential for clinical translation. Notably, the in vitro synergistic concentration exceeds the maximum oral bioavailable levels in vivo , and translational potential requires further in vivo verification.
Related
- 318 CAR-T and CAR-NK cell combination therapy targeting DLL3 or CD70 surface antigens promotes synergistic antitumor activity in small cell lung cancer
- Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
- Evaluation of antifungal and antibiofilm effects of supernatant cell-free supernatant (CFS) of Lactobacillus casei alone and in combination with nystatin against Candida albicans strains
- Enhanced antifungal efficacy of azole drugs through combination with usnic acid
- Nanoformulated silymarin enhances antifungal activity against resistant Candida albicans by reducing ergosterol and binding to cell envelope targets
BibTeX
@article{peng2026vitro,
title = {{In vitro synergistic antifungal activity of silybin-posaconazole combination against Candida auris}},
author = {Mengqi Peng and Xiaolei Zhu and Qinwen Hu and Yuqing Fan and Yuqi Mao and Xinrou Chen and Hanbo Qin and Heng Zhang and Yi Sun},
journal = {Frontiers in Microbiology},
year = {2026},
month = oct,
doi = {10.3389/fmicb.2026.1881511},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1881511/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - In vitro synergistic antifungal activity of silybin-posaconazole combination against Candida auris
AU - Mengqi Peng
AU - Xiaolei Zhu
AU - Qinwen Hu
AU - Yuqing Fan
AU - Yuqi Mao
AU - Xinrou Chen
AU - Hanbo Qin
AU - Heng Zhang
AU - Yi Sun
PY - 2026
DA - 2026/10/21
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1881511
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1881511/full
AB - Background: Candida auris infections pose a severe global public health threat. The hepatotoxicity of conventional azole antifungals and biofilm-mediated drug resistance adversely affect their clinical application. The natural component silybin (SLB) has both hepatoprotective and antimicrobial activities. Methods: This study was conducted in accordance with the CLSI M27-A4 standard, employing the broth microdilution plate method to evaluate the efficacy of SLB combined with itraconazole (ITR), voriconazole (VOR), posaconazole (POS) and fluconazole (FLC) against 10 C. auris strains. Synergistic effects were determined by measuring minimum inhibitory concentrations (MICs) and fractional inhibition concentration indices (FICIs). Potential synergistic mechanisms were investigated using ergosterol quantification, biofilm inhibition assay, reactive oxygen species (ROS) detection, Real-Time Quantitative PCR, SYTO9/PI double staining assay, and XTT assay. Results: Antifungal susceptibility testing showed that synergistic effects were most frequently observed when SLB was combined with POS (70% of strains), followed by SLB-VOR (50%) and SLB-ITR (30%). No synergism was detected for the SLB-FLC combination, while antagonism was observed in one strain for the SLB-ITR combination. The SLB-POS combination reduced ergosterol content, inhibited biofilm formation, and decreased the viability of preformed mature biofilms. It induced ROS accumulation, downregulated the expression of biofilm-associated genes ( bcr1 , efg1 , scf1 , mkc1 , erg2 , erg11 , als5 ) under planktonic conditions, and suppressed biofilm proliferative activity. Conclusion: The SLB-POS combination exhibits synergistic antifungal activity against C. auris. Its activity is associated with multiple pathways, including elevated oxidative stress responses and reduced ergosterol content. In addition, this combination downregulates biofilm-related gene expression and impairs the capacity of planktonic cells to form biofilms. These findings provide preliminary experimental evidence for addressing C. auris drug resistance and support further investigation of this combination as a therapeutic strategy with an improved safety-efficacy profile and potential for clinical translation. Notably, the in vitro synergistic concentration exceeds the maximum oral bioavailable levels in vivo , and translational potential requires further in vivo verification.
SN - 1664-302X
ER -